Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Most Read

  1. TapImmune begins patient enrolment for Phase ll trial of TPIV200
  2. Astellas reports positive Phase I data of gilteritinib combination
  3. Janssen reports positive Phase ll and lll data of imbruvica
  4. CEL-SCI reaches full enrolment in Phase lll trial of Multikine
  5. Nordic presents new Phase l/ll data of Betalutin

Latest Content

Nordic presents new Phase l/ll data of Betalutin

Nordic Nanovector has unveiled updated results from its LYMRIT 37-01 Phase l/ll clinical trial of Betalutin (177Lu-satetraxetan-lilotomab) to treat patients with relapsed/refractory (R/R) indolent NHL (iNHL) and third-line follicular lymphoma (3L FL).

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top